HC Wainwright Has Optimistic Outlook of NKTR Q1 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research note issued on Thursday, March 13th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.52) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The business had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million.

NKTR has been the topic of several other research reports. William Blair reaffirmed a “market perform” rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. B. Riley assumed coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $4.00 target price on the stock. Finally, Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research note on Friday. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $4.92.

Nektar Therapeutics Trading Up 1.4 %

Shares of NASDAQ:NKTR opened at $0.91 on Monday. The stock has a 50 day moving average of $0.88 and a 200 day moving average of $1.07. The company has a market cap of $167.73 million, a PE ratio of -1.08 and a beta of 0.65. Nektar Therapeutics has a 12-month low of $0.65 and a 12-month high of $1.93.

Institutional Investors Weigh In On Nektar Therapeutics

Several large investors have recently bought and sold shares of the business. Mackenzie Financial Corp grew its stake in shares of Nektar Therapeutics by 801.4% in the 4th quarter. Mackenzie Financial Corp now owns 469,769 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 417,651 shares in the last quarter. US Asset Management LLC bought a new position in shares of Nektar Therapeutics in the 4th quarter valued at about $31,000. Woodline Partners LP grew its position in Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after acquiring an additional 3,242,841 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Nektar Therapeutics during the fourth quarter worth approximately $130,000. Finally, Two Sigma Investments LP increased its stake in Nektar Therapeutics by 12.8% during the fourth quarter. Two Sigma Investments LP now owns 1,537,355 shares of the biopharmaceutical company’s stock worth $1,430,000 after acquiring an additional 174,185 shares during the last quarter. Institutional investors own 75.88% of the company’s stock.

Insider Buying and Selling

In related news, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the sale, the insider now directly owns 351,892 shares in the company, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the transaction, the insider now directly owns 326,904 shares of the company’s stock, valued at approximately $307,289.76. The trade was a 13.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 118,591 shares of company stock worth $112,525. 3.71% of the stock is owned by insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.